Biblio
2022
Perriello VMaria, Rotiroti MCaterina, Pisani I, Galimberti S, Alberti G, Pianigiani G, Ciaurro V, Marra A, Sabino M, Tini V, et al. IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML. Blood Adv. 2022.
Pirillo C, Birch F, Tissot FSimonne, Anton SGonzalez, Haltalli M, Tini V, Kong IY, Piot C, Partridge B, Pospori C, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022.